CD38 and Miyoshi myopathy: Despite the efficacy of anti-CD38 antibody therapies, especially when combined with immunomodulatory agents (IMIDs) and proteasome inhibitors (PIs), there is a hypothesis that resistance of MM may result from a complex interplay between genomic factors within tumor cells and specific immune TME patterns.